Jack A. Khattar - 22 Dec 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: President, CEO, Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 22 Dec 2023
Net transactions value: -$330,758
Form type: 4
Filing time: 26 Dec 2023, 17:00:28 UTC
Previous filing: 18 Dec 2023
Next filing: 22 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise	$0	+25,000	+2.9%	$0.000000	892,463	22 Dec 2023	Direct	F1
transaction	SUPN	Common Stock	Tax liability	$330,758	-11,958	-1.3%	$27.66	880,505	22 Dec 2023	Direct	F2
holding	SUPN	Common Stock						1,038,950	22 Dec 2023	By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Performance Share Unit	Options Exercise	$0	-25,000	-100%	$0.000000^*	0	22 Dec 2023	Common Stock	25,000	$0.000000	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022.
F2	Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3	On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.